1. Home
  2. MKZR vs DRMA Comparison

MKZR vs DRMA Comparison

Compare MKZR & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MacKenzie Realty Capital Inc.

MKZR

MacKenzie Realty Capital Inc.

HOLD

Current Price

$1.29

Market Cap

4.6M

Sector

N/A

ML Signal

HOLD

Logo Dermata Therapeutics Inc.

DRMA

Dermata Therapeutics Inc.

HOLD

Current Price

$1.24

Market Cap

5.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MKZR
DRMA
Founded
2012
2014
Country
United States
United States
Employees
N/A
9
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.6M
5.1M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
MKZR
DRMA
Price
$1.29
$1.24
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
16.8K
73.9K
Earning Date
05-14-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$650.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.50
$1.10
52 Week High
$6.99
$7.14

Technical Indicators

Market Signals
Indicator
MKZR
DRMA
Relative Strength Index (RSI) 25.87 44.20
Support Level N/A $1.14
Resistance Level $1.84 $1.40
Average True Range (ATR) 0.11 0.09
MACD -0.01 -0.01
Stochastic Oscillator 37.84 15.22

Price Performance

Historical Comparison
MKZR
DRMA

About MKZR MacKenzie Realty Capital Inc.

Mackenzie Realty Capital Inc is a company which is a Real estate investment trust (REIT). The company has one reportable segment, income-producing real estate properties which consists of activities related to investing in real estate. It is a real estate investment manager who utilizes an approach to real estate securities, often seeing opportunities that others overlook. Based in Orinda, California, MacKenzie Capital Management has specialized in discounted real estate securities and asset management.

About DRMA Dermata Therapeutics Inc.

Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin. The company's operates in one segment, which is the business of developing, branding, marketing, and commercializing direct to consumer skincare products.

Share on Social Networks: